Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020
An analysis of prospective radiographic assessments of 305 patients showed no adverse joint effects following treatment with ZILRETTA® Analysis of patient mobility indicated patients treated with ZILRETTA walked more steps per day in concert with pain reduction Survey of 1,000 patients with
View HTML
Toggle Summary Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020
BURLINGTON, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020 . Flexion’s management will host a conference call at
View HTML
Toggle Summary Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain
New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo High local concentrations of funapide, the active ingredient in FX301, were measured at the site of administration for the duration of
View HTML
Toggle Summary Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 19 th Annual Needham Virtual Healthcare Conference. The
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , April 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to seven new employees consisting of 9,265 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
View HTML
Toggle Summary Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic
Company signs exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (HK Tainuo) and Jiangsu Tainuo Pharmaceutical Co. Ltd. (Jiangsu Tainuo) for the development and commercialization of ZILRETTA® in Greater China License agreement provides Flexion with $10 million upfront payment, up to
View HTML
Toggle Summary Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $73.0 million for full-year 2019, representing more than 220% growth over 2018 Analysis of Phase 3b trial investigating ZILRETTA in patients with knee OA and synovitis indicates treatment
View HTML
Toggle Summary Flexion Therapeutics Names Melissa Layman Chief Commercial Officer
BURLINGTON, Mass. , March 11, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has been named Chief Commercial Officer (CCO). Ms. Layman joins Flexion with more than 25 years of commercial experience within the life science industry.
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , March 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of an aggregate of 8,500 stock options and 1,500 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2019 Financial Results on March 12, 2020
BURLINGTON, Mass. , March 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Thursday, March 12, 2020 .
View HTML